Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group.

Todd M Cooper,Michael J. Absalon,Todd A. Alonzo,Robert B. Gerbing,Kasey J. Leger,Betsy A. Hirsch,Jessica A. Pollard,Bassem I. Razzouk,Richard Aplenc,E. Anders Kolb

Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group.

2020

Todd M Cooper
Michael J. Absalon
Todd A. Alonzo
Robert B. Gerbing
Kasey J. Leger
Betsy A. Hirsch
Jessica A. Pollard
Bassem I. Razzouk
Richard Aplenc
E. Anders Kolb

PURPOSEEffective regimens are needed for children with relapsed acute myeloid leukemia (AML). AAML1421 is a phase I/II study of CPX-351, a liposomal preparation of daunorubicin and cytarabine. AAML...

Keywords:

Fludarabine
Oncology
Internal medicine
Cytarabine
Granulocyte colony-stimulating factor
phase i ii
Daunorubicin
Medicine
Myeloid leukemia

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations